Cspc Pharmaceutical Group Limited · HKEX:1093
Cspc Pharmaceutical — H1 2024 Earnings Presentation
36 slides from Cspc Pharmaceutical's earnings presentation, August 2024
Slide 1: 2024 Interim Results Presentation
2024 Interim Results Presentation Aug 2024
Slide 2: China's Leading Innovative Pharmaceutical Enterprise
China’s Leading Innovative Pharmaceutical Enterprise Manufacturing Capabilities R&D Capabilities • 10+ Production bases for pharmaceutical products • Nano formulation production capacity of 20M doses/year; Biologics fermentation capacity of 40,000L • Chemical drugs production capacity of OSD~30B tab
Slide 3: 2024 Interim Updates
2024 Interim Updates Regulatory Major Clinical Updates Trials Progress 2 new drug approvals: 25 IND approvals : • Mingfule (AIS)：The first of its kind product approved in China, it is the • China 22: CAR-T、RSV vaccine etc. second indication • North America 3: of which SYS6023 • Enshuxing (PD-1): The
Slide 4: Agenda
01 Financial Highlights 02 Business Review 03 R&D Capabilities 04 Pipeline 05 BD & ESG
Slide 5: Financial Highlights
01 Financial Highlights
Slide 6: Financial Highlights
Financial Highlights Revenue In: RMB’ M 16.28bn +1.3% 2024 1H 2023 1H Change 16.08bn Revenue 16,284 16,080 +1.3% Gross profit 11,655 11,238 +3.7% Gross profit margin 71.6% 69.9% +1.7% 2023 1H 2024 1H R&D expenses 2,542 2,304 +10.3% Underlying profit attributable Underlying profit attributable to 3,2
Slide 7: Revenue
Revenue Revenue by product category Revenue by therapeutic area 2023年 1-12月 2024 1H 2023 1H Change 2024 1H 2023 1H Change 2022年 1-12月Finished drugs 13,549 12,934 +4.8% Nervous system 5,236 4,553 +15.0% 变动 Oncology 2,683 2,988 -10.2% 984 1,040 -5.4% 成药 Bulk vitamin C Anti-infectives 2,307 2,143 +7.7%
Slide 8: Operating Profit
Operating Profit 2024 1H 2023 1H 2024 1H 2023 1H Change Change OPM OPM Finished drugs 3,488 3,192 +9.3% 25.7% 24.7% +1.0% Bulk vitamin C 67.6 67.6 +0.1% 6.9% 6.5% +0.4% Bulk antibiotics 186 71.4 +160.5% 21.4% 7.7% +13.7% Functional Food 175 331 -47.1% 19.9% 28.1% -8.2% and Others In: RMB’ M Note: ce
Slide 9: Business Review
02 Business Review
Slide 10: Finished Drugs Overview by Therapeutic Areas
Finished Drugs Overview by Therapeutic Areas Nervous • Major products: NBP (butylphthalide soft capsules, butylphthalide and sodium chloride injection), system Mingfule-AIS (recombinant human TNK tissue-type plasminogen activator for injection), Shuanling (pentoxifylline extended-release tablets, pe
Slide 11: Key Products Overview
Key Products Overview Anfulike NBP Xuanning Butylphthalide soft capsules and Levamlodipine maleate tablets and Amphotericin B cholesteryl sulfate injections dispersible tablets complex for injection • 1st Class 1 new drug of cardio- • The first Chinese innovative drug fully approved • Exclusive prod
Slide 12: Key Products Overview
Key Products Overview Duomeisu Jinyouli Doxorubicin Hydrochloride PEG-rhG-CSF injection liposome injection • The 1st long-acting white blood cell booster drug • Largest market share in China in China • The first player who passed • The provincial alliance collects products, and consistency evaluatio
Slide 13: Bulk Product Business, Functional Food and Others
Bulk Product Business, Functional Food and Others 01 02 03 Bulk vitamin C Bulk antibiotics Functional food and others • Major products: vitamin C, • Major products: 7-ACA (intermediate), • Revenue of the functional food and cefazolin sodium, penicillin potassium, others decreased mainly affected by
Slide 14: R&D Capability
03 R&D Capability
Slide 15: R&D Overview
R&D Overview • 8 national science & • Approx.300 projects under • 90 national projects • 5 R&D centres located technology qualifications development (approx. 130 in China & the U.S. innovative drug projects) • RMB 928M government • 2 national key labs grant support • R&D expenses in 2024 • 1948 IPs
Slide 16: Innovative R&D Platforms
Innovative R&D Platforms Nano- mRNA ADC formulation vaccine siRNA Mitoxantrone liposome Covid-19 mRNA PCSK9 siRNA and CLDN18.2 ADC Albumin-bound docetaxel vaccine 、RSV mRNA other chronic disease Paclitaxel cationic liposome vaccine and various Nectin-4 ADC drugs Cisplatin micelle pre
Slide 17: Nano-formulation Platform
Nano-formulation Platform Nano-formulation Novel Industrialized Novel drug carrier Novel drug delivery Novel preparation development and production technology design technology method manufacturing platform • Invented single-phase solution • Invented continuous flow • Invented Albumin • Invented amm
Slide 18: mRNA Vaccine Platform
mRNA Vaccine platform 1 Advantages of antigen 2 mRNA vaccine design 3 Manufacturing capabilities design • Mutation prediction platform • Base modification, UTR screening, • Manufacturing capabilities of CSPC codon optimization and structural • Top tier LNP R&D platform • The combination of bioinform
Slide 19: siRNA Platform
siRNA Platform 1 HTS screening platform 2 CMC platform 3 Manufacturing capabilities • Rational sequence design based • Build strong oligonucleotides • Manufacturing capabilities of on bioinformatics and CMC platform based on QbD CSPC experienced scientists strategy • Two GMP-compliant • Comprehensiv
Slide 20: ADC Platform
ADC Platform 1 Payload platform 2 Linker platform Multiple payload types for different cancer treatment mechanism of Various linker design for stability, PK and other purpose benefical for actions ADCs • microtubule inhibitor • Hydroflex platform ensures hydrophilicity, stability and PK • Topoisomer
Slide 21: Antibody & Fusion protein Platform
Antibody ＆ Fusion protein Platform Antibody-interferon fusion protein platform Structural advantages • Synergistic binding effect when targeting the same cell High expandability : quickly forms new molecules • Smaller molecular weight (smaller than that of conventional antibodies) >20 times Safer
Slide 22: CAR-T Platform
CAR-T Platform mRNA-LNP CAR-T Lower The cost of mRNA-LNP is much lower than cost virus vector Process mature mRNA-LNP and T cell production process it has no risk of tumorigenesis associated with Safety genomic integration, and significantly reduces adverse effects, notably CRS. High our innovation
Slide 23: Pipeline
04 Pipeline
Slide 24: Candidates under Clinical Trial Stage
Candidates under Clinical Trial Stage NBL-012 NBL-020 JMT101 CM310 Omalizumab NBL-015 CLDN18.2 CM326 IL23-P19 CLDN18.2 mAb TNFR2 EGFR mAb IL4R biosimilar ADC TSLP KN026 TG103 NBL-028 SYS6002 SYS6010 ALMB0166 Her2 BsAb Fc-GLP1 Batoclimab ALMB0168 CLDN6-CD137 Nectin-4 ADC EGFR ADC Cx43i mAb Cx43s mAb
Slide 25: Pipeline - Biological Agents
Pepline--Biological Agents 2 commercialized ，2 filed BLA ，8 under pivotal trial stage ，＞17 under clinical development stage ——Including various forms of drugs such as monoclonal antibody medicines, cell therapies, and Antibody-Drug Conjugates (ADCs). Major candidates Target Type PhI PhII PhII/III ND
Slide 26: Pipeline - Biological Agents
Pepline--Biological Agents Major candidates Target Type PhI PhII PhII/III期 NDA/BLA Launch Omalizumab IgE Bio-similar CSU、Asthma Ulsinumab IL-12/IL-23 Bio-similar Psoriasis Secukinumab IL-17A Bio-similar Psoriasis Pertuzumab HER2 Bio-similar Breast cancer KN026 HER2 BsAb 2L Gastric cancer（PhIII），1L b
Slide 27: Pipeline - New Formulations
Pepline--New Formulations 2 commercialized ，3 filed NDA，5 under pivotal trial stage ，＞5 under clinical development stage ——Including various forms of drugs such as liposomes, albumin and nanocrystals Major candidates Type PhI PhII PhII/III期 NDA/BLA Launch Mitoxantrone hydrochloride liposome New form
Slide 28: Pipeline - Small Molecule Drugs
Pepline--Small Molecule Drugs 1 filed NDA ，4 under pivotal trial stage ，＞ 10 under clinical development stage Major candidates Target Type PhI PhII PhII/III期 NDA/BLA Launch DBPR108 DPP-4 Small molecule T2DM Semaglutide injection GLP-1 Polypeptide T2DM（PhIII）、Obesity, Pilocarpine hydrochloride eye dr
Slide 29: Pipeline Products Launch Plan
14 Pipeline Products Launch Plan Simertinib (TKI) 14 Solid tumors mRNA vaccine RSV Amoxetine Anti-depressant mRNA vaccine VZV SYHX1901 Celecoxib /Tramadol 10 Psoriasis Hydrochloride Analgesia Semaglutide Vaccine Pregabalin extended- Obesity SYH2051（ATM inhibitor） Glioma release tablets Biological Ag
Slide 30: Major Data Release Plan for 2024
Major Data Release Plan for 2024 7 major datas published 9 research results were published SG001- cervical cancer-Ib Cancer Communications IF 20.1 JMT103-bone metastasis-PhIb ASCO online publication Mingfule-AIS-4.5~24h（TRACE-3） The New England Journal of Medicine simmitinib-tumor-PhI ASCO poster IF
Slide 31: Common Generics Launch Plan
Common Generics Launch Plan 20 generic drugs will be approved during the years 2024-2025; Additionally, approximately 30 projects currently in the pharmaceutical research phase, with plans to be approved before 2027 2024 2025 Dapagliflozin tablets Rabeprazole sodium Olaparib tablets Peramivir Inject
Slide 32: BD&ESG
05 BD&ESG
Slide 33: BD Strategic Layout and Path of Advancement
BD Strategic Layout and Path of Advancement Focusing on strategic domains, deepening BD strategies, and establishing an international BD ecosystem BD Product Positioning：Aligning closely with clinical needs, emphasizing clinical benefits, grasping international cutting-edge technology and product tr
Slide 34: BD Key Therapeutic Area Strategy for 2024
BD Key Therapeutic Area Strategy for 2024 Reinforce Leading Position in Explore Novel Therapeutic Areas and Established Areas Technology Platforms • Comprehensive Management of Stroke • Address primary and • Concentrate on well- • Focus on therapeutic nuclear • Strengthen differentiation in hematolo
Slide 35: Aim to Become an ESG Leader in Pharmaceutical Industry
Aim to Become an ESG Leader in Pharmaceutical Industry 2023 Environmental Protection Key Dates *The emission reduction taget is based on the emission in 2017 Continuous MSCI ESG rating upgrade Greenhouse gas emissions Emission of non-hazardous Discharge of hazardous A A A per unit of revenue waste (
Slide 36: Thanks!
E-mail Address of CSPC IR Team： ir@cspc.hk Thanks！
CSPC Pharmaceutical Group — H1 2024 Earnings Presentation on 6ix